Skip to main content

Advertisement

Table 3 Analysis of lipid and glycemic parameters

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

  n Baseline mean ± SD After administration mean ± SD Difference Percentage
TC (mmol/L) 3316 5.76 ± 1,03 5.45 ± 0.94 -0.31 ± 1.00 § -5.4%
LDL-C (mmol/L) 2226 3.19 ± 0.95 3.25 ± 0.81 0.05 ± 0.90 ‡ 1.6%
TG (mmol/L) 3316 3.72 ± 2.45 2.03 ± 1.50 -1.69 ± 2.08 § -45.4%
HDL-C (mmol/L) 2818 1.18 ± 0.32 1.34 ± 0.35 0.17 ± 0.25 § 14.0%
non-HDL-C (mmol/L) 2818 4.57 ± 0.99 4.11 ± 0.96 -0.46 ± 0.09 § -10.1%
TG/HDL 1818 3.49 ± 2.75 1.70 ± 1.59 -1.79 ± 2.31 § -51.3%
HbA1c (%) 3316 7.69 ± 1.52 7.22 ± 1.28 -0.47 ± 1.21 § -6.2%
FBG (mmol/L) 2387 9.00 ± 3.46 7.81 ± 2.89 -1.19 ± 3.33 § -13.2%
HOMA-R 102 4.46 ± 4.91 3.38 ± 3.83 -1.08 ± 4.78 † -24.3%
  1. "Difference" indicates the value for the change from baseline. "Percentage" indicates rate of change from baseline. A paired t-test was used to assess statistically significant differences from baseline for each group. Symbols for p values in this and the tables that follow: †: p < 0.05, ‡: p < 0.01, §: p < 0.001